Vericel Corporation ( (VCEL) ) has released its Q2 earnings. Here is a breakdown of the information Vericel Corporation presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vericel Corporation is a prominent player in the field of advanced therapies, focusing on sports medicine and severe burn care, with a portfolio that includes innovative cell therapies and specialty biologics designed to repair injuries and restore lives.
In its latest earnings report, Vericel Corporation announced a robust financial performance for the second quarter of 2025, marked by significant revenue growth and improved profitability. The company reported a 20% increase in total revenue, reaching $63.2 million, with notable growth in its MACI product line.
Key financial metrics highlighted in the report include a 21% growth in MACI revenue to $53.5 million and a gross margin increase to 74%. The company’s adjusted EBITDA saw a remarkable 112% growth, reaching $13.4 million, with an adjusted EBITDA margin increase of over 900 basis points to 21%. Vericel also reported a net loss reduction to $0.6 million, compared to $4.7 million in the previous year.
Vericel’s strategic advancements include the training of approximately 600 MACI Arthro surgeons and the receipt of FDA IND clearance for a Phase 3 MACI Ankle clinical study. The company is poised for continued growth, with plans to expand its MACI sales force and capitalize on positive trends in its business operations.
Looking ahead, Vericel’s management remains optimistic about sustaining strong revenue growth and profitability, reaffirming its full-year guidance for MACI revenue growth and profitability margins. The company is well-positioned to maintain its trajectory of success in the advanced therapies market.